Pediatric 1.3

algorithm-pediatric/src/main/resources/algorithms/pediatric/1.3/schemas/hepatoblastoma.json

@@ -4,7 +4,7 @@
   "version" : "1.3",
   "name" : "Hepatoblastoma",
   "title" : "Hepatoblastoma",
-  "notes" : "8970: C220 (all ages)\n\n**Note 1:** The following sources were used in the development of this schema\n* [Toronto Childhood Cancer Stage Guidelines, Version 2, May 2022](https://cancerqld.blob.core.windows.net/content/docs/childhood-cancer-staging-for-population-registries.pdf)\n* [Children’s Oncology Group - Newly Diagnosed with Hepatoblastoma or Hepatocellular Carcinoma](https://childrensoncologygroup.org/newly-diagnosed-with-hepatoblastoma-or-hepatocellular-carcinoma-)\n* [SEER Extent of Disease (EOD) 2018: Codes and Coding Instructions](https://seer.cancer.gov/tools/staging/eod/2018_Extent_of_Disease_General_Instructions.pdf)\n* [Summary Stage 2018 - SEER (cancer.gov)](https://seer.cancer.gov/tools/ssm/)\n\n**Note 2:** For Hepatoblastoma tumors, there are three different staging systems collected \n* Toronto Staging is based on the absence or presence of mets and is collected in Pediatric Mets\n* The Children’s Oncology Group (COG) for liver staging is used. \n   * Per this staging system, anything involved outside the liver is Stage IV. This is different than other staging used in the US that has adjacent organs not being a Stage IV\n    * Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets are used to derive the stage group\n* Pretext is collected as a SSDI and is based on clinical staging only",
+  "notes" : "8970: C220 (all ages)\n\n**Note 1:** The following sources were used in the development of this schema\n* [Toronto Childhood Cancer Stage Guidelines, Version 2, May 2022](https://cancerqld.blob.core.windows.net/content/docs/childhood-cancer-staging-for-population-registries.pdf)\n* [Childhood Liver Cancer Treatment (PDQ®) - NCI](https://www.cancer.gov/types/liver/hp/child-liver-treatment-pdq) \n* [SEER Extent of Disease (EOD) 2018: Codes and Coding Instructions](https://seer.cancer.gov/tools/staging/eod/2018_Extent_of_Disease_General_Instructions.pdf)\n* [Summary Stage 2018 - SEER (cancer.gov)](https://seer.cancer.gov/tools/ssm/)\n\n**Note 2:** For Hepatoblastoma tumors, there are three different staging systems collected \n* Toronto Staging is based on the absence or presence of mets and is collected in Pediatric Mets\n* The Children’s Oncology Group (COG) for liver staging is used. \n   * Per this staging system, anything involved outside the liver is Stage IV. This is different than other staging used in the US that has adjacent organs not being a Stage IV\n    * Pediatric Primary Tumor, Pediatric Regional Nodes and Pediatric Mets are used to derive the stage group\n* Pretext is collected as a SSDI and is based on clinical staging only",
   "schema_selection_table" : "schema_selection_hepatoblastoma",
   "schema_discriminators" : [ "behavior" ],
   "inputs" : [ {
@@ -139,19 +139,19 @@
     "id" : "toronto_stage",
     "name" : "Pediatric Stage",
     "initial_context" : [ {
-      "key" : "toronto_stage_group",
+      "key" : "pediatric_group",
       "value" : "90"
     }, {
-      "key" : "pediatric_group",
+      "key" : "toronto_stage_group",
       "value" : "90"
     } ],
     "tables" : [ {
       "id" : "pediatric_stage_70937",
       "inputs" : [ "pretext_clinical_staging", "ped_mets" ],
-      "outputs" : [ "toronto_stage_group", "pediatric_group" ]
+      "outputs" : [ "pediatric_group", "toronto_stage_group" ]
     } ]
   } ],
   "involved_tables" : [ "pediatric_primary_tumor_39067", "primary_site", "pediatric_mets_40773", "pediatric_regional_nodes_59828", "histology", "pretext_clinical_staging_39169", "year_dx_validation", "behavior", "pediatric_stage_70937", "schema_selection_hepatoblastoma" ],
-  "last_modified" : "2024-06-13T16:28:38.487Z",
+  "last_modified" : "2025-09-23T19:02:19.113Z",
   "on_invalid_input" : "CONTINUE"
 }

algorithm-pediatric/src/main/resources/algorithms/pediatric/1.3/tables/s_category_clinical_11368.json

@@ -5,8 +5,8 @@
   "name" : "S Category Clinical",
   "title" : "Testis Serum Markers (S) Clinical (pre orchiectomy)",
   "description" : "S Category Clinical combines the results of pre-orchiectomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.\n\nIn addition to T, N, and M, the S category is collected to stage Testicular cancers. There are three factors that make up the S stage: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactase dehydrogenase (LDH). These play an important role as serum tumor markers in the staging and monitoring of germ cell tumors and should be measured prior to removing the involved testicle. For patients with nonseminomas, the degree of tumor-marker elevation after the cancerous testicular has been removed is one of the most significant predictors of prognosis. Serum tumor markers are also very useful for monitoring all stages of nonseminomas and for monitoring metastatic seminomas because elevated marker levels are often the earliest sign of relapse.\n\nThere are several related data items pertinent to the collection of these variables.\n\nFor clinical staging \n* 3807: AFP Pre-Orchiectomy Lab Value\n* 3808: AFP Pre-Orchiectomy Range\n* 3848: hCG Pre-Orchiectomy Lab Value\n* 3849: hCG Pre-Orchiectomy Range\n* 3868: LDH Pre-Orchiectomy Range\n* 3923: S Category Clinical",
-  "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Pre-orchiectomy S category** \n* Code the pre-orchiectomy S category (Clinical S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Clinical Stage** \n* Clinical stage values are those based on physician statement or lab values at diagnosis, prior to orchiectomy, and prior to any systemic treatment.\n\n**Note 4:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available tests results meets the S2-3 criterion for that test, assign code 9 (SX).",
-  "last_modified" : "2024-03-30T23:56:00.435Z",
+  "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Pre-orchiectomy S category** \n* Code the pre-orchiectomy S category (Clinical S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Clinical Stage** \n* Clinical stage values are those based on physician statement or lab values at diagnosis, prior to orchiectomy, and prior to any systemic treatment.\n\n**Note 4:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available test results meet the S2-3 criterion for that test, assign code 9 (SX).",
+  "last_modified" : "2025-11-07T14:35:31.205Z",
   "definition" : [ {
     "key" : "s_category_clin",
     "name" : "Code",

algorithm-pediatric/src/main/resources/algorithms/pediatric/1.3/tables/s_category_pathological_46197.json

@@ -5,8 +5,8 @@
   "name" : "S Category Pathological",
   "title" : "Testis Serum Markers (S) Pathological (post-orchiectomy )",
   "description" : "S Category Pathological combines the results of post-orchiectomy Alpha Fetoprotein (AFP), Human Chorionic Gonadotropin (hCG) and Lactate Dehydrogenase (LDH) into a summary S value.\n\nIn addition to T, N, and M, the S category is collected to stage Testicular cancers. There are three factors that make up the S stage: alpha-fetoprotein (AFP), beta-human chorionic gonadotropin (beta-hCG), and lactase dehydrogenase (LDH). These play an important role as serum tumor markers in the staging and monitoring of germ cell tumors and should be measured prior to removing the involved testicle. For patients with nonseminomas, the degree of tumor-marker elevation after the cancerous testicular has been removed is one of the most significant predictors of prognosis. Serum tumor markers are also very useful for monitoring all stages of nonseminomas and for monitoring metastatic seminomas because elevated marker levels are often the earliest sign of relapse.\n\nThere are several related data items pertinent to the collection of these variables.\n\nFor pathological staging \n* 3805: AFP Post-Orchiectomy Lab Value\n* 3806: AFP Post-Orchiectomy Range\n* 3846: hCG Post-Orchiectomy Lab Value\n* 3847: hCG Post-Orchiectomy Range\n* 3867:  LDH Post-Orchiectomy Range\n* 3924: S Category Pathological",
-  "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Post-orchiectomy S Category** \n* Code the post-orchiectomy S category (Pathological S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Timing** \n* Pathological stage values are those based on physician statement or lab values **after orchiectomy and prior to adjuvant therapy**. \n\n**Note 4:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy lab values remain elevated, review the subsequent tests and use the lowest lab values (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 5:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available tests results meets the S2-3 criterion for that test, assign code 9 (SX).\n\n**Note 6:** **Normal Serum Tumor Markers (pre-orchiectomy)** \n* When all the serum tumor markers are normal pre-orchiectomy and they are not repeated post-orchiectomy, code 5.",
-  "last_modified" : "2024-03-30T23:58:29.747Z",
+  "notes" : "**Note 1:** **Physician Statement** \n* Code the S category as described by the physician. If the S category determined by available lab values or calculated by vendor software differs from the physician statement of the S category, the physician's statement takes precedence. \n\n**Note 2:** **Post-orchiectomy S Category** \n* Code the post-orchiectomy S category (Pathological S) according to the table below. This table is also available in AJCC 8th edition, Chapter 59, Testis.\n* For AFP, a lab value expressed in micrograms per liter (ug/L) is equivalent to the same value expressed in nanograms per milliliter (ng/ml).\n\n**Note 3:** **Timing** \n* Pathological stage values are those based on physician statement or lab values **after orchiectomy and prior to adjuvant therapy**. \n\n**Note 4:** **Lab values elevated after orchiectomy** \n* If the initial post-orchiectomy lab values remain elevated, review the subsequent tests and use the lowest lab values (normalization or plateau) prior to adjuvant therapy or before the value rises again.\n\n**Note 5:** **AFP, hCG, LDH** \n* All three lab values are needed for S0-S1. Only one elevated test is needed to assign S2-3. If any individual test is not available and none of the available test results meet the S2-3 criterion for that test, assign code 9 (SX).\n\n**Note 6:** **Normal Serum Tumor Markers (pre-orchiectomy)** \n* When all the serum tumor markers are normal pre-orchiectomy and they are not repeated post-orchiectomy, code 5.",
+  "last_modified" : "2025-11-07T14:35:50.893Z",
   "definition" : [ {
     "key" : "s_category_path",
     "name" : "Code",

algorithm-pediatric/src/main/resources/algorithms/pediatric/1.3/tables/schema_selection_hepatoblastoma.json

@@ -4,7 +4,7 @@
   "version" : "1.3",
   "name" : "Schema Selection Hepatoblastoma",
   "title" : "Schema selection for Hepatoblastoma",
-  "last_modified" : "2024-05-03T18:43:46.554Z",
+  "last_modified" : "2025-09-23T19:02:19.045Z",
   "definition" : [ {
     "key" : "site",
     "name" : "Primary Site",